EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution

Naohiro Matsunaga, Tomotaka Suzuki, Nozomi Nishitarumizu, Yoko Nakanishi, Aki Kondo, Yukiyasu Kato, Toru Ebina, Yoshiaki Marumo, Tomoyuki Nakamura, Takahiro Nakashima, Shiori Kinoshita, Tomoko Narita und 4 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2024.03.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Naohiro Matsunaga und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya,Aichi, Japan. Hauptthemen laut MEDLINE: Cytomegalovirus, Virus Activation, Cytomegalovirus Infections, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Anti-CD38 monoclonal antibodies (mAbs) have improved the prognosis of patients with plasma cell dyscrasia (PCD), but are also associated with increased infectious adverse events. Cytomegalovirus (CMV) is a common latent pathogen that is reactivated in immunocompromised individuals. Although CMV reactivation has mostly been reported after high-dose chemotherapy followed by stem cell transplantation in patients with PCD, cases of reactivation during anti-CD38 mAb therapy have been reported recently. Due to limited studies, we aimed to determine the frequency and impact of CMV reactivation during anti-CD38 mAb therapy. PATIENTS AND METHODS: This retrospective analysis included 154 consecutive patients with PCD who were treated with anti-CD38 mAbs at a single institution. RESULTS: Seventy-six patients were evaluated for CMV reactivation by CMV pp65 antigen testing, and 29 (38%) patients, including nine with newly diagnosed PCD, showed positive results. Patients who tested positive for the CMV pp65 antigen had substantially lower serum albumin levels than those who tested negative. However, the two groups showed no marked difference in the concurrent anti-PCD medications or baseline absolute lymphocyte count. Although most patients showing positive results in the CMV pp65 antigen test had mild or no symptoms, with fever being the most common symptom, some patients developed CMV end-organ disease. In addition, CMV reactivation interfered with the course of anti-PCD treatment in most patients, necessitating dose reductions, delays, and discontinuation of chemotherapy. CONCLUSION: This study provides an overview of the clinical impact of CMV reactivation in patients with PCD treated with anti-CD38 mAb-containing regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytomegalovirusVirus ActivationCytomegalovirus InfectionsAntibodies, MonoclonalParaproteinemiasHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultADP-ribosyl Cyclase 1Aged, 80 and overClinical Relevance

Stichwörter der Autor:innen

CMV pp65 antigenDaratumumabIsatuximabMultiple myeloma

Substanzen

Antibodies, MonoclonalADP-ribosyl Cyclase 1

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya,Aichi, Japan.
  • Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya,Aichi, Japan. Electronic address: suzuki92@med.nagoya-cu.ac.jp.

Zitieren

APA

Matsunaga, N., Suzuki, T., Nishitarumizu, N., Nakanishi, Y., Kondo, A., Kato, Y., Ebina, T., Marumo, Y., Nakamura, T., Nakashima, T., Kinoshita, S., Narita, T., Ri, M., Kusumoto, S., Komatsu, H., & Iida, S. (2024). Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.03.012

Vancouver

Matsunaga N, Suzuki T, Nishitarumizu N, Nakanishi Y, Kondo A, Kato Y, et al. Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.03.012

BibTeX
@article{Matsunaga2024,
  author = {Matsunaga, Naohiro and Suzuki, Tomotaka and Nishitarumizu, Nozomi and Nakanishi, Yoko and Kondo, Aki and Kato, Yukiyasu and Ebina, Toru and Marumo, Yoshiaki and Nakamura, Tomoyuki and Nakashima, Takahiro and Kinoshita, Shiori and Narita, Tomoko and Ri, Masaki and Kusumoto, Shigeru and Komatsu, Hirokazu and Iida, Shinsuke},
  title = {Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2024.03.012}
}
Kostenlos starten →